Testosterone Injectable Market Size & Share, by Dosage Form (Hypogonadism, Autoimmune Conditions, Genetic Disorders, Sex Organ Surgeries), Age Group (Adults, Geriatric, Paediatric), End-user (Hospitals, Homecare, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3973
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Testosterone Injectable Market size was over USD 2.16 billion in 2024 and is projected to reach USD 3.55 billion by 2037, growing at around 3.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of testosterone injectable is assessed at USD 2.3 billion.

The testosterone injectable is one of the most commonly found and popular types of hormone injection therapy all across the world. Owing to increased awareness about the advantages and efficiency of testosterone replacement therapy, the market is anticipated to gain more approval and recognition among patients and consumers.

The high healthcare expenditure with improved healthcare infrastructure is one of the major factors estimated to drive testosterone injectable market expansion during the forecast period. As per the Centers for Medicare & Medicaid Services (CMS), healthcare spending in the United States grew by 9.7% in 2020, reaching a value of USD 4.1 trillion. As a share of the nation’s Gross Domestic Product (GDP), health spending accounted for about 19.7%. 


Get more information on this report: Request Free Sample PDF

Testosterone Injectable Sector: Growth Drivers and Challenges

Growth Drivers

  • Rapidly Growing Geriatric Population Across the World – The growth in the aging population is giving rise to the testosterone injectable market expansion of testosterone injectables since testosterone organically reduces with the growing age and a lot of old people experience the symptoms of low testosterone. As per the statistics, the incidence of lower testosterone in men above the age of 60 years was 21.67%.
  • High Incidence of Testosterone Deficiency Among People Globally – Besides the aging population low testosterone can also appear in the younger generation too. Owing to various factors such as obesity, chronic illness, excessive lifestyle change, and environmental factors. The growing existence of testosterone deficiency among different age groups has propelled the demand for testosterone injectables. As per statistics, the prevalence of testosterone in young men, middlemen, and old men was 22.6%, 35.85%, and 35% respectively.
  • Availability to Various Treatment Centers – The accessibility to multiple diagnostics imaging centers, and treatment services in the past few years especially in emerging countries.

Challenges

  • Side Effects Associated with Testosterone Injectables – With advantages testosterone injectables do have a few side effects on the human body such as reduced sperm production, acne, skin reactions, sleep problem, hair loss, mood swings, and others. These side effects may limit the market value in the upcoming times.
  • Availability of Substitute Treatment Options
  • Regulatory Challenges

Testosterone Injectable Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

3.9%

Base Year Market Size (2024)

USD 2.16 billion

Forecast Year Market Size (2037)

USD 3.55 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Testosterone Injectable Segmentation

End Users (Hospitals, Homecare, Specialty Clinics)

The hospital segment in the testosterone injectable market is assumed to witness the largest revenue share of 45 % by the end of 2036. Hospitals play a vital role in the distribution and administration of testosterone injectables among people. Most endocrinologists, urologists, and general practitioners from hospitals prescribe testosterone injections to patients. Besides, hospitals also do have a proper environment for the administration of testosterone injectables. In addition, the hospital bed and supporting equipment have been increasingly used for the treatment of patients. Moreover, factors such as increasing spending on healthcare, insurance coverage, and prescribing practices are growth-driving factors for this segment. Spending on Medicaid increased by 9.2% to $734.0 billion in 2021. Spending on private health insurance increased by 5.8% to $1,211.4 billion in 2021.

Dosage Form (Hypogonadism, Autoimmune Conditions, Genetic Disorders, Sex Organ Surgeries)

Testosterone injectable market from the hypogonadism segment is set to witness the highest gain in the near future. Hypogonadism is one type of testosterone deficiency and it can be treated with the help of testosterone injectables which after entering the body increases the level of testosterone in a male body and brings it to normal range. Also, untreated hypogonadism can lead to health conditions such as heart disease or fatality. Therefore, the increasing prevalence of hypogonadism is estimated to propel the segment expansion in the projected period.

Our in-depth analysis of the global testosterone injectable market includes the following segments:

 

  Dosage Form

  • Hypogonadism
  • Autoimmune Conditions
  • Genetic Disorders
  • Sex Organ Surgeries

 

  Age Group

  • Adults
  • Geriatric
  • Pediatric

 

  End User

  • Hospitals
  • Homecare
  • Specialty Clinics

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Testosterone Injectable Industry- Regional Synopsis

North American Market Statistics

Europe industry is estimated to account for largest revenue share by 2037, propelled by presence of various medical centers, and rising government initiatives in the region.The factors such as growing disposable income, evolving lifestyle, and large access to developed healthcare services are estimated to boost the growth of the market in the region. Moreover, there has been a presence of advanced testosterone treatment in the countries such as the United States. According to a study, the frequency of testosterone treatment in the US has increased by 1.8 to 4-fold over the past 20 years.

European Market Forecast

Moreover, the testosterone injectable market in Europe is also projected to acquire a notable share during the estimated period. This can be propelled by the presence of various medical centers, and rising government initiatives. Moreover, there is easy access to various treatment facilities in developed countries such as the UK, which is further forecasted to surge the market’s growth in the region.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Testosterone Injectable Landscape

    • Bayer AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Endo Pharmaceuticals Inc.
    • Eli Lilly & Company
    • Kyowa Kirin International plc
    • Mylan N.V.
    • Novartis AG

In the News

  • January 2022- Endo Pharmaceuticals Inc. declared the release of data from a population pharmacokinetic (PK) modeling and simulation study, assessing the potential dosing flexibility of AVEED, a testosterone undecanoate, in hypogonadal men.
  • June 2021- Novartis AG announced that 177Lu-PSMA-617 upgraded entire survival and radiographic progression-free survival for men suffering from metastatic castration-resistant prostate cancer.

Author Credits:  Radhika Pawar


  • Report ID: 3973
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of testosterone injectable is assessed at USD 2.3 billion.

The testosterone injectable market size was over USD 2.16 billion in 2024 and is projected to reach USD 3.55 billion by 2037, growing at around 3.9% CAGR during the forecast period i.e., between 2025-2037. The market growth is due to rapidly growing geriatric population across the world, and the high prevalence of testosterone deficiency among people worldwide.

Europe industry is estimated to account for largest revenue share by 2037, propelled by presence of various medical centers, and rising government initiatives in the region.

The major players in the market are Bayer AG, Endo Pharmaceuticals Inc., Eli Lilly & Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG
Testosterone Injectable Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample